Global Anti Cancer Drug Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 120,000.00 Million |
 Market Size (Forecast Year) |
USD 297,000.00 Million |
 CAGR |
% |
| Major Markets Players |
Global Anti-Cancer Drug Market By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2030.
Anti-Cancer Drug Market Analysis and Size
Anti-cancer drug, also called antineoplastic drug are a drug that is effective in the treatment of malignant or cancerous disease. There are several major classes of anti-cancer drugs; these include alkylating agent, antimetabolites, natural products, and hormones. In addition, there are a number of drugs that do not fall within those classes, but that demonstrate anti-cancer activity and thus are used in the treatment of malignant disease. The term chemotherapy frequently is equated with the use of anti-cancer drugs, although it more accurately refers to the use of chemical compounds to treat disease generally.
Data Bridge Market Research analyses that the global anti-cancer drug market which was USD 1,20,000.00 million in 2022, would rocket up to USD 2,97,000.00 million by 2030, and is expected to undergo a CAGR of 12.0% during the forecast period. This indicates the market value. “Oral” dominates the “Route of Administration” segment of the anti-cancer drug market owing to the growing demand for medicines. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anti-Cancer Drug Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd (Switzerland), Genentech, Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline plc. (U.K.), Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Sanofi (France), and Bayer AG (Germany) among others. |
|
Market Opportunities |
|
Market Definition
The treatment of cancer is complicated in that the drugs used target human cells, albeit cells that have undergone genetic changes and are dividing at a fast and uncontrolled rate. However, certain anti-cancer drugs can differentiate to some degree between normal tissue cells and cancer cells, and the rate at which cancer cells proliferate may play a role in the apparent selectivity of agents.
Global Anti-Cancer Drug Market Dynamics
Drivers
- Increasing Prevalence of Cancer to Augment Market Growth
A growing number of the cancer incidence rate has increased to make it the second leading cause of death after cardiovascular disorders. Environmental factors such as tobacco smoking, changing diet patterns, urbanization, and extended post-reproductive lifespan are responsible for this phenomenon. For instance, according to the World Health Organization (WHO), cancer is a growing burden, and the number of new cancer cases is going to rise from 18.1 million in 2018 to 29.4 million by 2040. Therefore, the increasing prevalence of cancer is expected to boost the demand for the global oncology cancer drugs market during the forecast period. Furthermore, the rising awareness regarding cancer among the population is anticipated to favor the global market in the upcoming years.
- Presence of a Strong Pipeline of Drugs to Spur Growth Opportunities
The pace of change in the treatment of cancer is accelerating. A cluster of innovative treatments, often combined with other new or existing medicines, are emerging from the research and development pipeline. Many pharma companies are investing in these research activities of novel drugs for the treatment of cancer. For instance, in June 2019, Pfizer acquired Array BioPharma with an aim to expand its oncology presence and pipeline, starting with an approved combination therapy for melanoma that is now in phase 3 trial for a form of metastatic colorectal cancer. This, coupled with the growing preference for biosimilar and biologics entering the market, is projected to augment the market growth.
- Growing investment in healthcare facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further expected to create lucrative market opportunities.
Opportunities
Furthermore, an upsurge in the public-private funding for target research activities, rising demand for chronic diseases treatments using advanced drugs, and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising internet penetration rate, increasing adoption of arthroscopic surgeries, rise in the elderly and obese population globally, and increasing per capita expenditure on health care will further expand the market's growth rate in the future.
Restraints/Challenges
On the other hand, high costs associated with research and development proficiencies, limited infrastructural facilities, high costs associated with aesthetics, and a dearth of awareness in backward economies are expected to obstruct market growth. Also, the lack of favorable reimbursement scenarios and technology penetration in developing economies, the heavy customs duty imposed on medical devices, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.
This global anti-cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti-cancer drug market contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In June 2021 – Bayer AG announced that they entered into an agreement to acquire of Noria Therapeutics Inc. and PSMA Therapeutics Inc. Through this agreement, Bayer will have exclusive rights to the company’s investigational compound. This acquisition will help Bayer to expand their oncology portfolio.
- In April 2021– Sanofi announced that they have acquired Tidal Therapeutics, a pre-clinical biotech company responsible for the development of an mRNA based research platform. This acquisition will help Sanofi leverage this new technology platform to expand its research capabilities in the field of oncology, immunology and other disease areas.
Global Anti-Cancer Drug Market Scope
The global anti-cancer drug market is segmented on the basis of indication, drug, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Breast Cancer
- Blood Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Gynaecologic Cancer
- Lung Cancer
- Others
Drug
- Cytotoxics
- Hormonal Therapy
- Targeted Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Anti-Cancer Drug Market Regional Analysis/Insights
The global anti-cancer drug market is analysed, and market size insights and trends are provided by country, indication, drug, route of administration, end-users and distribution channel as referenced above.
The countries covered in the anti-cancer drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the anti-cancer drug market because of the strong base of healthcare facilities, the strong presence of major players in the market, increased cases of chronic diseases and the rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the rapid increase in people changing lifestyles, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global anti-cancer drug market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global anti-cancer drug market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global anti-cancer drug market. The data is available for the historic period 2010-2020.
Competitive Landscape and Global Anti-Cancer Drug Market Share Analysis
The global anti-cancer drug market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the anti-cancer drug market.
Some of the major players operating in the global anti-cancer drug market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genentech, Inc. (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.),
- Bristol-Myers Squibb Company (U.S.),
- GlaxoSmithKline plc. (U.K.),
- Eli Lilly and Company (U.S.),
- AstraZeneca (U.K.),
- Sanofi (France)
- Bayer AG (Germany)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
